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Abstract
Background: Metastasis to the lung may be the final step in the breast cancer-related morbidity. Conventional therapies
such as chemotherapy and surgery are somewhat successful, however, metastasis-related breast cancer morbidity remains
high. Thus, a novel approach to prevent breast tumor metastasis is needed.
Methodology/Principal Finding: Aerosol of lentivirus-based small hairpin osteopontin was delivered into mice with breast
cancer twice a week for 1 or 2 months using a nose-only inhalation system. The effects of small hairpin osteopontin on
breast cancer metastasis to the lung were evaluated using near infrared imaging as well as diverse molecular techniques.
Aerosol-delivered small hairpin osteopontin significantly decreased the expression level of osteopontin and altered the
expression of several important metastasis-related proteins in our murine breast cancer model.
Conclusion/Significance: Aerosol-delivered small hairpin osteopontin blocked breast cancer metastasis. Our results showed
that noninvasive targeting of pulmonary osteopontin or other specific genes responsible for cancer metastasis could be
used as an effective therapeutic regimen for the treatment of metastatic epithelial tumors.
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Introduction
Osteopontin (OPN) is a secreted glycophosphoprotein that is
believed to play a role in several apparently distinct cellular
processes [1]. High-level OPN expression is one of the
characteristics often associated with metastatic cancer cells [2–4].
As such, the metastatic activity of various cancer cells can be
significantly inhibited by downregulation of OPN expression [5–
8]. Many studies have shown a correlation between OPN and the
progression and severity of many cancers, including breast, colon,
lung, and prostate cancers. Particularly, elevated OPN levels and
poor prognoses are highly associated with metastatic breast cancer
[9,10]. Moreover, the lungs are one of the most susceptible organs
to breast cancer metastasis, which can differ in terms of evolution,
treatment, morbidity, and mortality [11].
Recent studies have shown that RNA interference (RNAi)-
mediated reduction of OPN expression may have therapeutic
efficiency for many types of cancers [12.13]. RNAi, which can be
induced in mammalian cells by small hairpin RNAs (shRNAs), is
an evolutionarily conserved surveillance mechanism that targets
double-stranded RNAs (dsRNAs) by sequence-specific silencing of
homologous genes [14]. Gene therapy involving RNAi is an
attractive strategy for the development of effective anticancer
therapies due to its low level of toxicity. However, low gene
transfection efficiency as well as technical difficulties associated
with delivery regimen hinder the practical application of in vivo
gene delivery. Especially, such problems clearly manisfest with
regards to gene therapy to the lung [15].
To solve this, aerosol delivery distributes material uniformly and
represents a noninvasive alternative for targeting genes to the lung.
In fact, our group has demonstrated that viral as well as nonviral
carrier-mediated gene delivery via inhalation may provide a means
of treatment for a wide range of pulmonary disorders and offer
numerous advantages over invasive modes of delivery [16,17,18].
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featuring shRNA-mediated RNAi has prompted us to develop a
novel approach for the prevention of lung metastasis of breast
cancer. In this study, shOPN was delivered into the lungs of mice
having breast cancer via a nose-only aerosol delivery system in
order to determine the preventive effects of suppressed OPN in
breast cancer metastasis to the lung. Here, we report that aerosol-
delivered shOPN blocked the metastasis of breast cancer to the
lung. Our results envision that noninvasive targeting of pulmonary
OPN or other specific genes responsible for cancer metastasis may
constitute an effective therapeutic regimen for the treatment of
metastatic epithelial tumors.
Materials and Methods
Lentivirus Construct for shOPN
The shRNA sequence targeting mouse OPN mRNA was
designed. The sequence for knockdown of murine OPN expression
was 59-CGAGGTGATAGCTTGGCTTAT-39. The scrambled
sequence 59-AAUCGCAUAGCGUAUGCCG-39 was used as a
control. shRNA was generated based on the above siRNA
sequence and cloned into the pENTR/U6
TM entry vector
(Invitrogen, Carlsbad, CA, USA). Cassettes containing a U6
promoter and the shRNA target sequences were transferred into a
lentivirus vector (pLenti6/BLOCK-iT
TM-DEST vector) by fol-
lowing the manufacturer’s instructions. Recombinant lentiviral
vectors were packaged using the ViraPower
TM Lentiviral Packag-
ing Mix (Invitrogen), after which the virus titer was determined
using a HIV-1 p24 ELISA KIT (PerkinElmer Life Sciences,
Boston, MA, USA).
In Vivo Aerosol Delivery of Lentiviral shOPN
Five-week-old female Balb/c nude mice were purchased from
JoongangLaboratoryAnimalInc(Seoul,Korea).Animalswerekept
in the laboratory animal facility at a constant temperature and
relative humidity of 2362uCa n d5 0 620%, respectively, under a
12 h light/dark cycle. Balb/c nude mice were injected with MDA-
MB 231 cells (1610
6 cells/each in PBS) (Korean Cell Line Bank,
Figure 1. Lentivirus-shOPN decreases metastasis to the lung. (A) Gross morphological examination of the lung after aerosol delivery of
shOPN for 1 or 2 months. White circles indicate neoplastic nodules observed in the lung. (B) Histopathological examination of lung after aerosol
delivery of shOPN for 1 or 2 months. Magnification (6200) scale bar: 50 mm.
doi:10.1371/journal.pone.0015623.g001
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mice were divided into 3 groups (the control group was left
untreated while the other two groups were exposed to aerosol
containing lentivirus-shOPN or lentivirus-scrambled) [16,17,18].
The mice were then placed in a nose-only inhalation chamber and
exposed to aerosol containing lentivirus solution (50 ml) containing
40 ng/ml of lentivirus-shOPN or scrambled control twice a week
for 1 or 2 months, respectively. At the end of each time period, the
mice were sacrificed and lungs were collected. During necropsy,
neoplastic lesions on the lung surfaces were carefully counted under
a microscope, as described by Singh et al [21]. All methods used in
this study were approved by the Animal Care and Use Committee
at Seoul National University (SNU-100303-1).
Western Blot Analysis
Protein concentration of the homogenized lysates was measured
using a Bradford kit (Bio-Rad, Hercules, CA, USA). Equal
amounts (50 mm) of protein were separated by SDS–PAGE (10–
15%) and transferred onto nitrocellulose membranes (Amersham
Pharmacia, Cambridge, UK). After membranes were blocked in
T-TBS containing 5% skim milk for 1 h, immunoblotting was
performed by incubation overnight at 4uC with primary antibodies
corresponding to OPN (R&D system, Minneapolis, MN, USA),
CD44v6 (Millipore, Billerica, MA, USA), MMP-9 (Abcam,
Billerica, MA, USA), MMP-2 (Novus, Littleton, CO, USA),
VEGF (Santa Cruz, CA, USA), and PCNA (Santa Cruz, CA,
USA) diluted 1:1000 v/v in 5% skim milk, followed by incubation
with second antibodies conjugated to horseradish peroxidase
(HRP) for 3 h at room temperature or overnight at 4uC. After
washing, the bands-of-interests were analyzed using a luminescent
image analyzer LAS-3000 (Fujifilm, Tokyo, Japan).
Histopathological Examinationand
Immunohistochemistry (IHC)
After formalin-fixation, paraffin-embedded tissue sections were
cut to 5 mm and transferred to Plus slides (Fisher Scientific,
Pittsburgh, PA, USA). For histological analysis, tissue sections were
stained with hematoxylin and eosin (H&E). For IHC, the tissues
were deparaffinized in xylene (10 min 62 times) and rehydrated
through an alcohol gradient (each 5 min). The slides were then
boiled in TE buffer (pH 9.0) for retrieval process, washed in tap
water, and incubated in 3% hydrogen peroxide (AppliChem,
Darmstadt, Germany) for 30 min to quench endogenous perox-
idase activity. After washing in phosphate-buffered saline (PBS),
the tissue sections were incubated with 3% bovine serum albumin
in PBS for 1 h at room temperature in order to block unspecific
binding sites. Primary antibodies were applied to tissue sections
overnight at 4uC. On the second day, tissue slides were washed
and incubated with secondary HRP-conjugated antibodies for 1 h
at room temperature. After washing, tissue sections were
counterstained with Mayer’s Hematoxylin (DAKO, Carpinteria,
CA, USA) and washed with xylene. Cover slips were then
mounted using Permount (Fisher Scientific), and the slides were
reviewed using a light microscope (Carl Zeiss, Thornwood, NY,
USA). Staining of PCNA and OPN for quantification by IHC
analysis was performed using the In Studio version 3.01 program
(Pixera, San Jose, CA, USA). Staining intensity was assessed by
counting the number of positive cells in randomly selected fields
viewed at appropriate magnification through the objective lens.
Wound Healing Assay
MDA-MB-231 cells were cultured to sub-confluence in 6-well
plates. Streaks were made in the monolayer culture using 10 ml
pipette tips. After washing away suspended cells, the remaining
cells were treated with medium containing lentivirus-shOPN and
lentivirus-scrambled. The progress of migration was photographed
immediately 24 h after wounding.
Statistical Analysis
The results of the Western blot analysis, IHC, and wound
healing assay are expressed as the mean 6 S.E.M of 3
independent experiments. Statistical analyses were performed
following analysis of Student’s t-test whenever the data consisted of
only two groups. Quantification of Western blot analysis was
performed using the Multi Gauge version 3.0 program (Fujifilm).
Results
Aerosol Delivery of Lentivirus-shOPN Decreases Breast
Cancer Metastasis to Lung
To determine whether or not aerosol delivery of shOPN affects
breast cancer metastasis to the lung, lentivirus-shOPN was
Table 1. Summary of tumor incidence in mouse model of metastatic breast cancer.
Group
Number of
mouse Tumor numbers/mouse
Adenocarcinoma
incidence Adenoma
Total .1.5 mm
" ,1.5 mm
£ ++
$ +
¥
Control 4 6.2560.87 1.561.73 4.7561.94 2 1 1
1month scrambled 4 662.61 261.83 461.08 1 1 2
shOPN 4 2.1361.03
** N.D. 2.1361.03
## N.D. 2
2months scrambled 4 9.2560.87 2.561.29 6.7560.87 1 1 2
shOPN 4 2.3860.63
##** N.D. 2.3860.63
## N.D. 2
Difinition of abbreviations: shOPN=small hairpin Osteopontin. N.D.=Not Detected.
Breast cancer model mice were exposed to lentivirus-shOPN twice a week for 1 or 2 months. After 1 or 2 months, the mice were sacrificed, lungs were collected, and the
lesions on the lung surfaces were counted. Incidence and tumor number of lung mass were compared. Data were expressed as means 6 S.E.M.
£: Number of tumors of smaller than 1.5 mm in diameter.
": Number of tumors of greater than 1.5 mm in diameter.
¥: Adenocarcinoma grade was mild.
$: Adenocarcinoma grade was moderate.
##:p ,0.01 compared to scrambled group.
**: p,0.01 compared to control group.
doi:10.1371/journal.pone.0015623.t001
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mice. Gross morphological examination demonstrated that
shOPN decreased lung tumor mass in the shOPN group
compared to the control and scrambled group (Fig. 1A).
Suppression of lung tumor metastasis was further confirmed by
histolopathological analysis (Fig. 1B). Nodules formed in the lungs
of the control and scrambled group were typical adenocarcinomas.
However, the shOPN group demonstrated only a tumor mass,
Figure 2. Effect of Aerosol-delivered shOPN on expression level of OPN. (A) Western blot analysis of OPN. (B) Densitometric analysis of OPN.
(C) Immunohistochemical analysis of OPN. Magnification: 6400. Scale bar: 20 mm. (D) Comparison of OPN labeling index. Each bar represents the
mean6 S.E.M (n=3). *Statistically significant different (P,0.05) compared to control group. **Statistically different (P,0.01) compared to control
group.
#Statistically different (P,0.05) compared to scrambled control.
##Statistically different (P,0.01) compared to scrambled control.
doi:10.1371/journal.pone.0015623.g002
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preventive effects against lung metastasis of breast cancer are
clearly summarized in Table 1.
Aerosol Delivery of shOPN Decreases OPN Expression in
the Lung
To investigate the expression level of OPN in the lungs of
breast cancer model mice after shOPN aerosol delivery, Western
blot analysis was carried out. Lentiviral shOPN significantly
decreased expression of OPN in the lungs of breast cancer model
mice (Fig. 2A). Quantification of the bands-of-interest recon-
firmed the Western blot results (Fig. 2B). IHC analysis also
demonstrated that aerosol-delivered shOPN decreased expression
of OPN compared to the control and scrambled group (Fig. 2C).
Relative staining intensity for OPN clearly confirmed this finding
(Fig. 2D).
Aerosol Delivery of shOPN Suppresses Tumor Invasion
and Angiogenesis
Angiogenesis, the growth of new blood vessels, is known to
promote tumor progression and metastasis [22]. Tumor invasion
involves tumor cell penetration or infiltration into adjacent tissue
and is related to the onset of metastasis [23]. In this study, we
examined changes in the expression of angiogenesis- and invasion-
related proteins by Western blotting. Our results clearly showed
that aerosol delivery of shOPN significantly decreased the
expression levels of CD44v6, VEGF, MMP-2, and MMP-9, as
observed by densitometric analysis (Fig. 3A and 3B).
Aerosol Delivery of shOPN Suppresses Cell Proliferation
in the Lung
Expression of proliferating cell nuclear antigen (PCNA) is
increased in several types of cancers. Moreover, it has been
postulated as a useful prognostic parameter for certain cancers
[24]. Therefore, we determined the expression level of PCNA by
Western blot analysis, which revealed that aerosol-delivered
shOPN decreased PCNA expression in the lung of breast cancer
model mice (Fig. 4A). Densitometric analysis further confirmed the
Western blot results (Fig. 4B). Furthermore, IHC analysis showed
that aerosol-delivered shOPN significantly decreased the expres-
sion level of PCNA compared to the control and scrambled group
(Fig. 4C). The relative staining intensity also clearly confirmed this
(Fig. 4D).
shOPN Inhibits Cell Migration
To investigate whether or not inhibition of OPN expression
would reduce the migration of breast adenocarcinoma cells
(MDA-MB231), wound healing assay was carried out. Our results
showed that shOPN reduced the number of migrated cells after
24 h. Specifically, lentivirus-shOPN significantly inhibited motility
of MDA-MB231 cells compared to the control and scrambled
group (Fig. 5B).
Discussion
Tumor metastasis may be divided into three different steps;
separation of cancer cells from the primary tumor, circulation and
migration of the cells through blood vessels to other organs, and
finally, inhabitation of the cells in the target organs [25]. Many
lines of evidence have reported that metastasis of breast cancer
cells to the lungs probably occurs through the sentinel lymph node
[26]. Therefore, metastasis to the lymph nodes can be a key
prognostic factor of advanced disease status with the possibility of
cancer cell migration from the original site to other more distant
sites. [26,27,28]. In this study, with the aid of NIR imaging
technology, we were able to detect the migration of cancer cells to
the sentinel lymph node 2 weeks after injection of MDA-MB 231
cells into the mammary fat pad (Fig. S1). This finding is what
caused us to perform aerosol gene delivery 2 weeks after cancer
cell injection in order to focus on the 3
rd step of metastasis for
preventing development of breast cancer cells to the lung.
Different approaches to gene delivery to the lung, such as
intravenous injection and intratracheal instillation, have been
reported in animal models [29.30]. These strategies are invasive or
may not be appropriate for targeting pulmonary tissues. However,
aerosol delivery is known to be an efficient method for delivering
genes directly to the lungs [16,17,18]. Viral vectors have been
demonstrated to be highly effective for gene delivery, and among
these, lentiviral vectors provide for efficient gene transfer in cells
and mediate stable, high-level transgene expression both in vitro
and in vivo [17,31,32]. Therefore, in this study, we downregulated
OPN expression in breast cancer model mice via aerosol delivery
of lentiviral hOPN in order to investigate whether or not aerosol-
delivered shOPN decreases metastatic spread of breast cancer cells
to the lung.
OPN is a matricellular protein that is expressed in different
tissues in the body, but mostly in bone. It is also produced by
cancer cells and is known to play a crucial role in the growth,
progression, and metastasis of cancer [33]. Actually, in breast
cancer progression and metastasis, OPN is known as an important
mediator, and it has been investigated as a potential therapeutic
target in the treatment of breast cancer [34]. Patients of breast
cancer suffering metastasis to the lung are faced with limited
treatment options [35]. Since secreted phosphoproteins are readily
accessible in the extracellular environment, OPN has gained much
attention as an attractive therapeutic target for the blockade of
tumor growth and metastasis. OPN binds to certain CD44
variants and integrin receptors [36,37]. Expression of CD44 and
its variant isoforms is associated with aggressive behavior of
various tumors [38,39]. Actually, CD44 variant 6 (CD44v6) is
known to be overexpressed in lung and breast cancers [40,41]. In
this regard, our results showing significant suppression of CD44v6
by shOPN (Fig. 3) holds potential that shOPN delivery may be
used in the treatment of breast cancer metastasis.
VEGF is a potent angiogenic cytokine with critical roles in
tumor angiogenesis. VEGF produces may biological effects such as
endothelial cell mitogenesis, migration, induction of proteinases
leading to remodeling of the extracellular matrix, increased
vascular permeability, and maintenance of the survival of newly
formed blood vessels [42]. Overexpression of VEGF has been
observed in a variety of human tumors; thus, increased VEGF
expression in tumors has been established as an accurate
biomarker of invasiveness, vascular density, metastasis, and
recurrence [42,43,44]. Many researchers have demonstrated that
co-expression of VEGF and OPN is well correlated with
Figure 3. Western Blot Analysis of CD44v6, VEGF, MMP-9, and MMP-2. (A) Expression of CD44v6, VEGF, MMP-2, and MMP-9 in the lung. (B)
Bands-of-interest were further analyzed by densitometry. Each bar represents the mean6 S.E.M (n=3). *Statistically different (P,0.05) compared to
control group. **Statistically different (P,0.01) compared to control group.
#Statistically different (P,0.05) compared to scrambled control.
##Statistically different (P,0.01) compared to scrambled control.
doi:10.1371/journal.pone.0015623.g003
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More importantly, patients with VEGF-positive and OPN-positive
lung adenocarcinoma suffer poor results due to increased
postoperative metastasis and poor prognoses [46]. MMP-2 and
MMP-9 are among the known factors that promote tumor cell
motility, invasiveness, and epithelial-mesenchymal transition.
MMPs are known to degrade dense extracellular matrix molecules
(ECM) such as laminin, collagens, fibronectin, and proteoglycans
in order to create space for tumor cell migration. Moreover,
MMPs are known to activate certain growth factors associated
with the ECM or cell surface [47]. Our results showed that aerosol
delivery of shOPN significantly decreased the expression levels of
CD44v6, VEGF, MMP-2, and MMP-9, strongly suggesting that
suppression of OPN by lentiviral shOPN via aerosol can effectively
inhibit migration, angiogenesis, and invasion of breast cancer cells
into the lung. Epithelial cell proliferation in normal and cancerous
lungs can be measured efficiently by quantifying the percentage of
tumor cells positive for PCNA [48]. Our results showed that
aerosol-delivered shOPN significantly decreased expression of
PCNA. Therefore, combined with the effective suppression of
several important angiogenic factors (Fig. 3), suppression of OPN
by aerosol-delivered shOPN could probably prevent breast cancer
cell metastasis into the lung.
In summary, our results demonstrated that aerosol-delivered
shOPN suppressed the migration and invasion of breast cancer
cells, leading to reduction of metastasis from the breast to the lung.
Therefore, we suggest that aerosol gene delivery may prove to be a
useful noninvasive model of gene delivery and that noninvasive
Figure 5. Wound Healing Assay. (A) Cell migration was inhibited by lentivirus-shOPN. MDA-MB 231 cells were grown up to 90% confluence, a
single wound was made in the center of the cell monolayer and cell debris was removed by washing. After 24 h of incubation, the wound closure
areas were visualized under an inverted microscope with a magnification 6100, (B) and the migrated cells were counted. **Statistically different
(P,0.01) compared to control group.
##Statistically different (P,0.01) compared to scrambled control.
doi:10.1371/journal.pone.0015623.g005
Figure 4. Effect of Aerosol-delivered shOPN on expression level of PCNA. (A) Western blot of PCNA. (B) Densitometric analysis of PCNA. (C)
Immunohistochemical analysis of PCNA. Magnification: 6400. Scale bar: 20 mm. (D) Comparison of PCNA labeling index. Each bar represents the
mean6 S.E.M (n=3). *Statistically different (P,0.05) compared to control group. **Statistically different (P,0.01) compared to control group.
#Statistically different (P,0.05) compared to scrambled control.
##Statistically different (P,0.01) compared to scrambled control.
doi:10.1371/journal.pone.0015623.g004
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metastasis may be an effective therapeutic regimen for the
treatment of metastatic epithelial tumors.
Supporting Information
Figure S1 Image of mouse model of metastatic breast
cancer. (A) Tagged MDA-MB 231 with NEO-LIVETM 797
(Biterials, Seoul, Korea) was injected into mouse mammary fat pad
(red signals) and NIR signal detected using an image analyzer
(MaestroTM, CRi, MA, USA). (B) In the mouse foot pad, NEO-
LIVETM 675 (Biterials) was injected (green signals) and NIR
signal detected using the same image analyzer. (C) Merged
imaging picture. (D) Magnification image of indicated area (white
square). (E) After NIR detection, sentinel lymph node was
removed and stained with H&E. Red square indicates metastasis
area of breast cancer cells (MDA-MB 231). Black dotted line
indicates the boundary between invasion area and lymph node. C;
Cortex, PF; Primary follicle. Scale bar: 50 mm( 6200) (F)
Magnified image of indicated area (red box of E). Scale bar: 20
mm( 6400)
(TIF)
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